Timbercreek Financial Corp

TF-T

Analysis and Opinions about TF-T

Signal
Opinion
Expert
TOP PICK
TOP PICK
December 10, 2019
Bond-like, they're very good at mezzanine and commercial lending. They distribute what they get and are conservatively balanced (balance sheet). They know their markets. It's like a mortgage-lending situation. They earn 7% rates of return, no more or less. A very stable investment, acting like a bond proxy. (Analysts’ price target is $9.96)
Show full opinionHide full opinion
Bond-like, they're very good at mezzanine and commercial lending. They distribute what they get and are conservatively balanced (balance sheet). They know their markets. It's like a mortgage-lending situation. They earn 7% rates of return, no more or less. A very stable investment, acting like a bond proxy. (Analysts’ price target is $9.96)
HOLD
HOLD
March 28, 2017

There was a real disconnect between two entities within the company they decided to merge and that allowed them to trade closer to NAV. They increased their distribution recently. He still likes it.

Show full opinionHide full opinion

There was a real disconnect between two entities within the company they decided to merge and that allowed them to trade closer to NAV. They increased their distribution recently. He still likes it.

PAST TOP PICK
PAST TOP PICK
July 20, 2015

(Top Pick July 8/14, Up 0.44%) There is an anomaly because this senior mortgage is trading below timber creek. This is a temporary thing and it should trade up.

Show full opinionHide full opinion

(Top Pick July 8/14, Up 0.44%) There is an anomaly because this senior mortgage is trading below timber creek. This is a temporary thing and it should trade up.

PAST TOP PICK
PAST TOP PICK
September 10, 2014

(Top Pick Aug 07’13, Up 6.20%) Short term financing for apartments or developers that don’t want to go to the banks. 10-15% discount to NAV.

Show full opinionHide full opinion

(Top Pick Aug 07’13, Up 6.20%) Short term financing for apartments or developers that don’t want to go to the banks. 10-15% discount to NAV.

TOP PICK
TOP PICK
July 8, 2014

A mortgage investment company. Trades at a discount. 75% of their book is first mortgages. They are at about 44% loan to value. If real estate falls apart they still get all their money back. This is almost equivalent to a bond.

Show full opinionHide full opinion

A mortgage investment company. Trades at a discount. 75% of their book is first mortgages. They are at about 44% loan to value. If real estate falls apart they still get all their money back. This is almost equivalent to a bond.

TOP PICK
TOP PICK
August 7, 2013

This is a fund that is about to be turned into a corporate entity. He thinks they are the best in class to becoming experts. This is a more senior lending where you have a lot more loan-to-value protection. They lend on short-term lending agreements to hospitals or apartment buildings where there is less risk.

Show full opinionHide full opinion

This is a fund that is about to be turned into a corporate entity. He thinks they are the best in class to becoming experts. This is a more senior lending where you have a lot more loan-to-value protection. They lend on short-term lending agreements to hospitals or apartment buildings where there is less risk.

DON'T BUY
DON'T BUY
August 15, 2006

At the bottom end of his database. Reported 9% negative earnings. Last $.35 in 2006. Great technology, but it seems to be taking forever to get it out into the marketplace.

Show full opinionHide full opinion

At the bottom end of his database. Reported 9% negative earnings. Last $.35 in 2006. Great technology, but it seems to be taking forever to get it out into the marketplace.

BUY
BUY
March 13, 2006

This stock is at the bottome 15% of the database. Long on promise short on delivery type of company. They have tests for Avian flu and genetic tests for newborns. Signed up a large number of testing facilities in the U.S, but this is only used in a small range. He has owned in the past but does not own currently. If Avian flu passes to humans this company would benefit.

Show full opinionHide full opinion

This stock is at the bottome 15% of the database. Long on promise short on delivery type of company. They have tests for Avian flu and genetic tests for newborns. Signed up a large number of testing facilities in the U.S, but this is only used in a small range. He has owned in the past but does not own currently. If Avian flu passes to humans this company would benefit.

DON'T BUY
DON'T BUY
July 21, 2005

Quest (DGX-N) has done a "toe-in-the-water" on their product giving them a limited exposure to it. Was the product successful and will Quest and others broaden out their purchases? Very interesting product. Ranks poorly in his overall model at this point.

Show full opinionHide full opinion

Quest (DGX-N) has done a "toe-in-the-water" on their product giving them a limited exposure to it. Was the product successful and will Quest and others broaden out their purchases? Very interesting product. Ranks poorly in his overall model at this point.

WEAK BUY
WEAK BUY
July 9, 2004

Speculative. Good technology. Less expensive technologies.

Show full opinionHide full opinion

Speculative. Good technology. Less expensive technologies.

BUY
BUY
May 13, 2004

Very volatile. Have a tiny percentage in a couple of their funds. Have superior technology in genetic testing. An early stage company. Should see breakeven by the end of the year.

Show full opinionHide full opinion

Very volatile. Have a tiny percentage in a couple of their funds. Have superior technology in genetic testing. An early stage company. Should see breakeven by the end of the year.

BUY
BUY
February 12, 2004

Trades in a band of $.40 to $.50. They have a methodology which should be quite powerful for them in 2004. Have a one-year lead over Pfizer. Speculative but pretty good prospects.

Show full opinionHide full opinion

Trades in a band of $.40 to $.50. They have a methodology which should be quite powerful for them in 2004. Have a one-year lead over Pfizer. Speculative but pretty good prospects.

BUY
BUY

Profitable. Good product.

BUY WEAKNESS
BUY WEAKNESS
October 13, 2000

In a good area Too speculative Watch for new clients

Show full opinionHide full opinion

In a good area Too speculative Watch for new clients

Showing 1 to 14 of 14 entries
  • «
  • 1
  • »

Timbercreek Financial Corp(TF-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Timbercreek Financial Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Timbercreek Financial Corp(TF-T) Frequently Asked Questions

What is Timbercreek Financial Corp stock symbol?

Timbercreek Financial Corp is a Canadian stock, trading under the symbol TF-T on the Toronto Stock Exchange (TF-CT). It is usually referred to as TSX:TF or TF-T

Is Timbercreek Financial Corp a buy or a sell?

In the last year, there was no coverage of Timbercreek Financial Corp published on Stockchase.

Is Timbercreek Financial Corp a good investment or a top pick?

Timbercreek Financial Corp was recommended as a Top Pick by Paul Gardner, CFA on 2019-12-10. Read the latest stock experts ratings for Timbercreek Financial Corp.

Why is Timbercreek Financial Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Timbercreek Financial Corp worth watching?

0 stock analysts on Stockchase covered Timbercreek Financial Corp In the last year. It is a trending stock that is worth watching.

What is Timbercreek Financial Corp stock price?

On 2020-09-21, Timbercreek Financial Corp (TF-T) stock closed at a price of $8.34.